Eiger Shifts Focus After Phase II Failure In PAH

 
• By Joseph Haas

Finding no improvement with ubenimex in PAH, Eiger ends development but continues with the drug in lymphedema, plus hepatitis D and post-bariatric hypoglycemia candidates.

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments

More from Clinical Trials

More from R&D